538 / 1481
Feng et al.
IJROBP
2007;28:2732-8.
Feng et al.
J Clin Oncol
2010;28:2732-8.
• 73 patients (prospective trial):
•
Oropharyngeal cancer stage III-IV
•
IMRT + concurrent chemo:
•
63 Gy/35 fractions to the PTV1-”elective”
neck;
•
59.5 Gy/35 fractions to the PTV2-
”elective” neck.
•
Limiting dose to the oral cavity and
swallowing structures-minus-PTV-T/N.
• Omitting medial retropharyngeal lymph
nodes from the CTV of “elective” neck.
Target volume reduction (1)